Cancer immunotherapy by fusions of dendritic cells and tumor cells (Q37773276)

22 August 2017

1 reference

title

Cancer immunotherapy by fusions of dendritic cells and tumor cells (English)

1 reference

22 August 2017

1 reference

1 reference

Shigeo Koido

1

1 reference

22 August 2017

Eiichi Hara

2

1 reference

22 August 2017

Sadamu Homma

3

1 reference

22 August 2017

Toshifumi Ohkusa

4

1 reference

22 August 2017

Jianlin Gong

5

1 reference

22 August 2017

Hisao Tajiri

6

1 reference

22 August 2017

1 January 2009

1 reference

22 August 2017

1 reference

22 August 2017

1

1 reference

22 August 2017

1

1 reference

22 August 2017

49-62

1 reference

The dendritic cell system and its role in immunogenicity

22 August 2017

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Dendritic cells and the control of immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Human dendritic cells transfected with either RNA or DNA encoding influenza matrix protein M1 differ in their ability to stimulate cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Cell fusion: from hybridoma to dendritic cell-based vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

The tissue distribution of the B7-2 costimulator in mice: abundant expression on dendritic cells in situ and during maturation in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

High levels of a major histocompatibility complex II-self peptide complex on dendritic cells from the T cell areas of lymph nodes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Therapeutic immune response induced by electrofusion of dendritic and tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Comparative analysis of antigen loading strategies of dendritic cells for tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Enhanced tumor-specific long-term immunity of hemagglutinating [correction of hemaggluttinating] virus of Japan-mediated dendritic cell-tumor fused cell vaccination by coadministration with CpG oligodeoxynucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

A new genetic method to generate and isolate small, short-lived but highly potent dendritic cell-tumor cell hybrid vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Tumor-derived TGF-beta reduces the efficacy of dendritic cell/tumor fusion vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Preventive antitumor activity against hepatocellular carcinoma (HCC) induced by immunization with fusions of dendritic cells and HCC cells in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Comparative analysis of DC fused with tumor cells or transfected with tumor total RNA as potential cancer vaccines against hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Engineered fusion hybrid vaccine of IL-4 gene-modified myeloma and relative mature dendritic cells enhances antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Electrofusion of syngeneic dendritic cells and tumor generates potent therapeutic vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

The epithelial mucin, MUC1, of milk, mammary gland and other tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Induction of antigen-specific antitumor immunity with adenovirus-transduced dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Assessment of fusion cells from patient-derived ovarian carcinoma cells and dendritic cells as a vaccine for clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Induction of antigen-specific CD4- and CD8-mediated T-cell responses by fusions of autologous dendritic cells and metastatic colorectal cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Dendritic cells fused with human cancer cells: morphology, antigen expression, and T cell stimulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Immunotherapy using fusions of autologous dendritic cells and tumor cells showed effective clinical response in a patient with advanced gastric carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

In vitro generation of cytotoxic and regulatory T cells by fusions of human dendritic cells and hepatocellular carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Whole tumor antigen vaccination using dendritic cells: comparison of RNA electroporation and pulsing with UV-irradiated tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Generation and functional assessment of antigen-specific T cells stimulated by fusions of dendritic cells and allogeneic breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Induction of impaired antitumor immunity by fusion of MHC class II-deficient dendritic cells with tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

CD4 T cells and their role in antitumor immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Development of antigen-specific CD8+ CTL in MHC class I-deficient mice through CD4 to CD8 conversion

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

High frequency of allele-specific down-regulation of HLA class I expression in uveal melanoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

CD4+ T-regulatory cells: toward therapy for human diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

The significance of Treg cells in defective tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Expression of a soluble TGF-beta receptor by tumor cells enhances dendritic cell/tumor fusion vaccine efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Tolerogenic dendritic cells: cytokine modulation comes of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Fusions of dendritic cells with breast carcinoma stimulate the expansion of regulatory T cells while concomitant exposure to IL-12, CpG oligodeoxynucleotides, and anti-CD3/CD28 promotes the expansion of activated tumor reactive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

The allogeneic response and tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Dendritic cells are dysfunctional in patients with operable breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Cancer immunotherapy by fusions of dendritic and tumour cells and rh-IL-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Dendritic cell vaccine therapy by immunization with fusion cells of interleukin-2 gene-transduced, spleen-derived dendritic cells and tumour cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Prevention of gastrointestinal tumors based on adenomatous polyposis coli gene mutation by dendritic cell vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Superior protective and therapeutic effects of IL-12 and IL-18 gene-transduced dendritic neuroblastoma fusion cells on liver metastasis of murine neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Paired Toll-like receptor agonists enhance vaccine therapy through induction of interleukin-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Toll-like receptor ligands energize peptide vaccines through multiple paths

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Functional control of regulatory T cells and cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Regulatory T cells and toll-like receptors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Streptococcal preparation OK-432 promotes fusion efficiency and enhances induction of antigen-specific CTL by fusions of dendritic cells and colorectal cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Recruitment of T lymphocytes and induction of tumor necrosis factor in thyroid cancer by a local immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Antitumor effects of systemic and local immunization with a CTL-directed peptide in combination with a local injection of OK-432.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

21 January 2018

The heat-shock proteins

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Immunotherapy for human cancer using heat shock protein-peptide complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

How is the immune response affected by hyperthermia and heat shock proteins?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Heat-shock proteins in cancer vaccines: agents of antigen cross-presentation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Role of the major heat shock proteins as molecular chaperones

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Heat shock protein 70: role in antigen presentation and immune stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

CD8+ T cell cross-priming via transfer of proteasome substrates

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Synergistic induction of antigen-specific CTL by fusions of TLR-stimulated dendritic cells and heat-stressed tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Hybrid cell vaccination for cancer immune therapy: first clinical trial with metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Tumour-dendritic hybrid cell vaccination for the treatment of patients with malignant melanoma: immunological effects and clinical results.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Cancer immunotherapy--the endgame begins

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Tumor rejection by disturbing tumor stroma cell interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Tumor Rejection by Modulation of Tumor Stromal Fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Combined chemoimmunotherapy of solid tumours: improving vaccines?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

Selection and characterization of MUC1-specific CD8+ T cells from MUC1 transgenic mice immunized with dendritic-carcinoma fusion cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.1.49

21 January 2018

Identifiers

DOI

10.2217/1750743X.1.1.49

1 reference

22 August 2017

1 reference